Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology

Area of Science:

• Genetics
• Molecular Biology
• Oncology

Background:

• Neurofibromatosis type 2 (NF2) is an inherited disorder causing nervous system tumors, primarily schwannomas.
• It stems from mutations in the NF2 gene, which codes for the schwannomin protein (merlin).
• Most NF2 mutations lead to truncated, non-functional schwannomin.

Purpose of the Study:

• To investigate the molecular mechanisms underlying NF2 pathogenesis, focusing on mutations in exon 2 of the NF2 gene.
• To identify the interaction partners of schwannomin and their role in NF2 development.

Main Methods:

• Analysis of NF2 gene mutations, including in-frame deletions and missense mutations in exon 2.
• Conditional knockout mouse models with exon 2 deletion in Schwann cells.
• Biochemical assays to study protein-protein interactions between schwannomin and paxillin.

Main Results:

• Mutations in NF2 exon 2 lead to defective schwannomin, causing schwannoma development in mice.
• Paxillin directly binds to schwannomin at residues 50-70, encoded by exon 2.
• This interaction is crucial for schwannomin's localization to the plasma membrane and association with beta 1 integrin and erbB2.

Conclusions:

• Mutations in NF2 exon 2 disrupt the paxillin-schwannomin interaction, impairing schwannomin localization and function.
• This disruption provides a specific pathogenic mechanism for NF2 development in patients with exon 2 mutations.
• Targeting this interaction could offer therapeutic strategies for NF2.